DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Lotus Eye Hospital and Institute Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 1 hr ago·8 Oct 2026, 5:30 am

Lotus Eye Hospital and Institute

Lotus Eye Hospital and Institute Limited has confirmed to stock exchanges that it has obtained a crucial compliance certificate under SEBI's Regulation 74(5). This regulation specifically mandates that a company must ensure the delivery of securities to its shareholders within a strict timeframe. The receipt of this certificate signals that the company has successfully met these regulatory requirements for the transfer of shares.

For investors, this development is a positive signal, as it confirms the company's adherence to corporate governance standards. It effectively removes a regulatory uncertainty regarding share transfers, ensuring that existing and potential shareholders can expect a smooth and timely process for their holdings. This compliance is a standard but necessary step for maintaining the integrity of the company's shareholding structure.

Investors should now focus on the company's upcoming quarterly results and its operational expansion plans. Since this news is procedural, it does not directly impact the company's core business performance. Keeping an eye on the hospital's patient footfall and upcoming facility launches will provide better insights into its growth trajectory than this regulatory update.